BAX and metabolic dysfunction-associated steatotic liver disease: This activation inhibits ROS production, regulates the Bcl-2/Bax ratio and PARP cleavage, and reduces apoptosis, in both HFD-induced and FFA-induced HepG2 cells, thereby delaying the process of NAFLD [30].